About Omnicell Technologies (NASDAQ:OMCL)
Omnicell, Inc. provides automation and business analytics software solutions for medication and supply management in healthcare worldwide. The company operates through two segments, Automation and Analytics, and Medication Adherence. It offers Omnicell Automated Dispensing Cabinets, a dispensing system, which automates the management and dispensing of medications; SinglePointe, a software product that controls medications; AnywhereRN, a software which remotely queue medications from automated dispensing cabinets; Omnicell Analytics and Pandora Analytics reporting and data analytics tools; and Anesthesia Workstation that manages anesthesia supplies and medications. The company also provides XR2 Central Pharmacy System, a hospital pharmacy robotics system; Central and Satellite Pharmacy Manager, an automated pharmacy storage and retrieval system; Controlled Substance Management, a controlled substance inventory management system; OmniLinkRx, a prescription routing system; and WorkflowRx, an automated pharmacy storage, retrieval, and packaging system. In addition, it offers Omnicell Supply Management System, an automated dispensing system; Omnicell Tissue Center, which manages the chain of custody for bone and tissue specimens; OptiFlex MS that manages medical and surgical supplies; OptiFlex SS, a module for the perioperative areas; and OptiFlex CL, a module for the cardiac catheterization lab and other procedure areas. Further, the company provides IV Solutions; enterprise analytics and solutions; Omnicell Interface Software; Mach4 Pharma Systems Medimat, a robotic dispensing system; Omnicell SupplyX subscription software; RFID solutions; and consumable medication blister cards, packaging equipment, and ancillary products and services to institutional pharmacies. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was founded in 1992 and is headquartered in Mountain View, California.
Industry, Sector and Symbol
Industry Electronic computers
Sub-IndustryHealth Care Technology
SectorMedical
SymbolNASDAQ:OMCL
CUSIP68213N10
Phone650-251-6100
Debt
Debt-to-Equity Ratio0.38%
Current Ratio1.73%
Quick Ratio1.28%
Price-To-Earnings
Trailing P/E Ratio239.44
Forward P/E Ratio56.00
P/E Growth3.67
Sales & Book Value
Annual Sales$716.16 million
Price / Sales2.34
Cash Flow$1.5428 per share
Price / Cash27.95
Book Value$13.64 per share
Price / Book3.16
Profitability
EPS (Most Recent Fiscal Year)$0.18
Net Income$20.60 million
Net Margins2.88%
Return on Equity1.54%
Return on Assets0.77%
Miscellaneous
Employees2,350
Outstanding Shares38,860,000
Omnicell Technologies (NASDAQ:OMCL) Frequently Asked Questions
What is Omnicell Technologies' stock symbol?
Omnicell Technologies trades on the NASDAQ under the ticker symbol "OMCL."
How were Omnicell Technologies' earnings last quarter?
Omnicell Technologies (NASDAQ:OMCL) posted its quarterly earnings results on Thursday, February, 1st. The company reported $0.54 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $0.52 by $0.02. The business had revenue of $198.26 million for the quarter, compared to analyst estimates of $205.50 million. Omnicell Technologies had a return on equity of 1.54% and a net margin of 2.88%. The firm's revenue was up 13.6% on a year-over-year basis. During the same period last year, the company earned $0.37 EPS. View Omnicell Technologies' Earnings History.
When is Omnicell Technologies' next earnings date?
What guidance has Omnicell Technologies issued on next quarter's earnings?
Omnicell Technologies issued an update on its FY18 earnings guidance on Thursday, February, 1st. The company provided earnings per share (EPS) guidance of $1.85-2.05 for the period, compared to the Thomson Reuters consensus EPS estimate of $1.98. The company issued revenue guidance of $780-800 million, compared to the consensus revenue estimate of $809.67 million.Omnicell Technologies also updated its Q1 guidance to $0.22-0.28 EPS.
What price target have analysts set for OMCL?
7 equities research analysts have issued twelve-month price objectives for Omnicell Technologies' stock. Their forecasts range from $44.00 to $67.00. On average, they anticipate Omnicell Technologies' stock price to reach $56.1429 in the next twelve months. View Analyst Ratings for Omnicell Technologies.
What are Wall Street analysts saying about Omnicell Technologies stock?
Here are some recent quotes from research analysts about Omnicell Technologies stock:
- 1. Cantor Fitzgerald analysts commented, "On Monday, April 2, CNBC.com reported that Walmart and perhaps Amazon were looking to acquire PillPack." (4/3/2018)
- 2. According to Zacks Investment Research, "Omnicell’s fourth-quarter 2017 performance was impressive with year-over-year increase in both earnings and revenues. Further, both of the company’s segments witnessed year-over-year growth. We are encouraged to note that the company is working on product innovation through R&D. The company is expected to gain from its recent launches and strategic partnerships. Its recent product launches include the XR2 Automated Central Pharmacy System and the IVX Workflow, IVX Workflow creates a significant technological advancement for sterile compounding workflow processes, enabling pharmacies to safely and efficiently compound and prepare IV doses.Also, improvement in margin is also encouraging. However, a tough competitive landscape acts as a dampener. Over the past month, Omnicell’s shares have been trading below the broader industry." (2/2/2018)
Who are some of Omnicell Technologies' key competitors?
Some companies that are related to Omnicell Technologies include Enerplus (ERF), Array Biopharma (ARRY), AMN Healthcare Services (AMN), UDG Healthcare (UDHCF), Spark Therapeutics (ONCE), Inogen (INGN), Tesaro (TSRO), Indivior (INDV), China Biologic Products (CBPO), Clovis Oncology (CLVS), arGEN-X BV (ARGX), Halozyme Therapeutics (HALO), Immunomedics (IMMU), Amicus Therapeutics (FOLD), Nevro (NVRO), Foundation Medicine (FMI), Magellan Health (MGLN) and Emergent BioSolutions (EBS).
Who are Omnicell Technologies' key executives?
Omnicell Technologies' management team includes the folowing people:
- Mr. Randall A. Lipps, Founder, Exec. Chairman, Chief Exec. Officer and Pres (Age 61)
- Mr. Peter J. Kuipers, Exec. VP & CFO (Age 46)
- Mr. Nhat H. Ngo, Exec. VP of Marketing, Strategy & Bus. Devel. (Age 45)
- Mr. J. Christopher Drew, Pres of North American Automation and Analytics (Age 52)
- Mr. Robin G. Seim, Pres of Global Automation and Medication Adherence (Age 58)
Has Omnicell Technologies been receiving favorable news coverage?
Media stories about OMCL stock have trended somewhat positive on Friday, according to Accern Sentiment Analysis. Accern identifies positive and negative press coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Omnicell Technologies earned a media sentiment score of 0.04 on Accern's scale. They also gave media headlines about the company an impact score of 46.33 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the near term.
How do I buy shares of Omnicell Technologies?
Shares of OMCL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Omnicell Technologies' stock price today?
One share of OMCL stock can currently be purchased for approximately $43.17.
How big of a company is Omnicell Technologies?
Omnicell Technologies has a market capitalization of $1.73 billion and generates $716.16 million in revenue each year. The company earns $20.60 million in net income (profit) each year or $0.18 on an earnings per share basis. Omnicell Technologies employs 2,350 workers across the globe.
How can I contact Omnicell Technologies?
Omnicell Technologies' mailing address is 590 EAST MIDDLEFIELD ROAD, MOUNTAIN VIEW CA, 94043. The company can be reached via phone at 650-251-6100 or via email at [email protected]
MarketBeat Community Rating for Omnicell Technologies (OMCL)
MarketBeat's community ratings are surveys of what our community members think about Omnicell Technologies and other stocks. Vote "Outperform" if you believe OMCL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OMCL will underperform the S&P 500 over the long term. You may vote once every thirty days.
Omnicell Technologies (NASDAQ:OMCL) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
7 Wall Street analysts have issued ratings and price targets for Omnicell Technologies in the last 12 months. Their average twelve-month price target is $56.1429, suggesting that the stock has a possible upside of 30.20%. The high price target for OMCL is $67.00 and the low price target for OMCL is $44.00. There are currently 2 hold ratings and 5 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.71 | 2.71 | 2.86 | 2.86 |
| Ratings Breakdown: | 0 Sell Rating(s)
2 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
2 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $56.1429 | $56.1429 | $55.1429 | $51.8571 |
| Price Target Upside: | 30.20% upside | 24.07% upside | 7.81% upside | 1.32% downside |
Omnicell Technologies (NASDAQ:OMCL) Consensus Price Target History
Omnicell Technologies (NASDAQ:OMCL) Analyst Ratings History
Show:
(Data available from 4/20/2016 forward)
Omnicell Technologies (NASDAQ:OMCL) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Omnicell Technologies (NASDAQ OMCL) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 3.71%
Omnicell Technologies (NASDAQ OMCL) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 4/16/2018 | Dan S Johnston | EVP | Sell | 11,284 | $44.95 | $507,215.80 | 46,430 |  |
| 4/12/2018 | Peter J Kuipers | Insider | Sell | 724 | $46.00 | $33,304.00 | 56,970 | |
| 3/15/2018 | Gary S Petersmeyer | Director | Sell | 575 | $44.43 | $25,547.25 | | |
| 3/6/2018 | Randall A Lipps | Chairman | Sell | 8,186 | $44.21 | $361,903.06 | 224,206 | |
| 12/18/2017 | Peter J Kuipers | CFO | Sell | 1,926 | $51.69 | $99,554.94 | 40,544 | |
| 11/17/2017 | Dan S Johnston | EVP | Sell | 14,613 | $47.81 | $698,647.53 | 43,621 | |
| 11/17/2017 | Peter J Kuipers | VP | Sell | 4,724 | $47.74 | $225,523.76 | 40,544 | |
| 11/6/2017 | Jorge R Taborga | VP | Sell | 6,295 | $48.69 | $306,503.55 | 50,013 | |
| 10/2/2017 | Peter J Kuipers | VP | Sell | 3,532 | $50.96 | $179,990.72 | 40,714 | |
| 9/15/2017 | Robin Gene Seim | EVP | Sell | 9,780 | $48.97 | $478,926.60 | 55,896 | |
| 9/5/2017 | Gary S. Petersmeyer | Director | Sell | 1,000 | $51.73 | $51,730.00 | | |
| 9/1/2017 | Randall A. Lipps | Chairman | Sell | 10,625 | $52.00 | $552,500.00 | | |
| 8/18/2017 | Dan S Johnston | EVP | Sell | 16,400 | $48.86 | $801,304.00 | 51,621 | |
| 8/15/2017 | Robin Gene Seim | EVP | Sell | 15,109 | $50.86 | $768,443.74 | 58,144 | |
| 8/9/2017 | Peter J Kuipers | VP | Sell | 18,054 | $50.31 | $908,296.74 | 44,236 | |
| 8/8/2017 | J Christopher Drew | VP | Sell | 11,375 | $51.16 | $581,945.00 | 139,201 | |
| 8/7/2017 | Jorge R Taborga | VP | Sell | 20,719 | $50.98 | $1,056,254.62 | 53,270 | |
| 8/1/2017 | Randall A Lipps | Chairman | Sell | 40,000 | $49.76 | $1,990,400.00 | 196,551 | |
| 7/28/2017 | Randall A Lipps | Chairman | Sell | 37,500 | $46.00 | $1,725,000.00 | 196,551 | |
| 6/19/2017 | Randall A Lipps | Chairman | Sell | 31,527 | $42.87 | $1,351,562.49 | 196,551 | |
| 6/5/2017 | Randall A Lipps | Chairman | Sell | 9,900 | $43.00 | $425,700.00 | 208,982 | |
| 5/26/2017 | James T Judson | Director | Sell | 12,148 | $41.50 | $504,142.00 | 19,130 | |
| 5/25/2017 | Gary S Petersmeyer | Director | Sell | 2,200 | $41.41 | $91,102.00 | 21,075 | |
| 5/19/2017 | Dan S Johnston | EVP | Sell | 16,400 | $40.67 | $666,988.00 | 61,696 | |
| 5/9/2017 | J Christopher Drew | VP | Sell | 10,625 | $40.97 | $435,306.25 | 152,057 | |
| 4/25/2017 | Randall A Lipps | Chairman | Sell | 18,200 | $41.00 | $746,200.00 | 208,982 | |
| 3/10/2017 | Gary S Petersmeyer | Director | Sell | 2,658 | $37.45 | $99,542.10 | 20,085 | |
| 2/21/2017 | Sara J White | Director | Sell | 3,443 | $38.06 | $131,040.58 | 43,214 | |
| 11/18/2016 | Dan S Johnston | EVP | Sell | 8,850 | $33.65 | $297,802.50 | 58,877 | |
| 11/18/2016 | Jorge R Taborga | VP | Sell | 2,068 | $33.66 | $69,608.88 | 47,223 | |
| 11/8/2016 | J Christopher Drew | VP | Sell | 20,000 | $31.95 | $639,000.00 | 139,844 | |
| 9/12/2016 | Gary S Petersmeyer | Director | Sell | 2,000 | $37.98 | $75,960.00 | 17,987 | |
| 9/8/2016 | Gary S Petersmeyer | Director | Sell | 2,400 | $39.39 | $94,536.00 | 17,987 | |
| 9/6/2016 | Gary S Petersmeyer | Director | Sell | 2,000 | $39.02 | $78,040.00 | 19,987 | |
| 9/2/2016 | Gary S Petersmeyer | Director | Sell | 3,000 | $38.52 | $115,560.00 | 19,987 | |
| 8/19/2016 | Dan S Johnston | EVP | Sell | 8,850 | $36.93 | $326,830.50 | 64,877 | |
| 8/19/2016 | Jorge R Taborga | VP | Sell | 1,778 | $36.92 | $65,643.76 | 49,073 | |
| 8/11/2016 | Randall A Lipps | Chairman | Sell | 37,425 | $37.37 | $1,398,572.25 | 192,325 | |
| 8/9/2016 | J Christopher Drew | VP | Sell | 15,000 | $37.89 | $568,350.00 | 139,844 | |
| 8/9/2016 | James T Judson | Director | Sell | 6,250 | $37.98 | $237,375.00 | 15,300 | |
| 8/4/2016 | Gary S Petersmeyer | Director | Sell | 8,750 | $37.84 | $331,100.00 | 19,987 | |
| 7/29/2016 | Jorge R Taborga | VP | Sell | 10,023 | $40.00 | $400,920.00 | 49,073 | |
| 7/6/2016 | Robin Gene Seim | EVP | Sell | 5,302 | $34.75 | $184,244.50 | 55,420 | |
| 7/1/2016 | Robin Gene Seim | EVP | Sell | 3,645 | $35.00 | $127,575.00 | 55,420 | |
| 6/6/2016 | Jorge R Taborga | VP | Sell | 25,979 | $33.00 | $857,307.00 | 50,734 | |
| 5/24/2016 | Gary S Petersmeyer | Director | Sell | 6,250 | $31.22 | $195,125.00 | 15,557 | |
| 5/20/2016 | Dan S Johnston | EVP | Sell | 8,850 | $30.73 | $271,960.50 | 73,105 | |
| 5/20/2016 | Jorge R Taborga | VP | Sell | 1,933 | $30.73 | $59,401.09 | 52,667 | |
| 5/10/2016 | J Christopher Drew | VP | Sell | 15,000 | $31.63 | $474,450.00 | 144,573 | |
| 5/5/2016 | Sara J White | Director | Sell | 2,000 | $31.76 | $63,520.00 | 40,433 | |
| 4/29/2016 | Robin Gene Seim | EVP | Sell | 6,407 | $31.00 | $198,617.00 | 59,619 | |
| 4/26/2016 | Jorge R Taborga | VP | Sell | 23,827 | $30.00 | $714,810.00 | 52,667 | |
| 4/26/2016 | Robin Gene Seim | EVP | Sell | 767 | $30.00 | $23,010.00 | 60,386 | |
| 2/19/2016 | Dan S Johnston | EVP | Sell | 8,850 | $27.41 | $242,578.50 | 79,716 | |
| 2/19/2016 | Jorge R Taborga | VP | Sell | 1,685 | $27.42 | $46,202.70 | 54,806 | |
| 2/11/2016 | Randall A. Lipps | CEO | Sell | 40,000 | $27.81 | $1,112,400.00 | 204,705 | |
| 2/9/2016 | J Christopher Drew | VP | Sell | 15,000 | $27.57 | $413,550.00 | 145,355 | |
| 12/18/2015 | Nhat H. Ngo | VP | Sell | 4,069 | $28.71 | $116,820.99 | 23,431 | |
| 11/17/2015 | Dan S. Johnston | VP | Sell | 2,500 | $28.00 | $70,000.00 | 66,393 | |
| 11/10/2015 | J Christopher Drew | VP | Sell | 25,000 | $26.79 | $669,750.00 | 137,180 | |
| 11/9/2015 | Dan S. Johnston | VP | Sell | 2,700 | $27.29 | $73,683.00 | 66,393 | |
| 10/13/2015 | Gary S. Petersmeyer | Director | Sell | 670 | $31.66 | $21,212.20 | 15,557 | |
| 8/13/2015 | Robin Gene Seim | CFO | Sell | 23,946 | $35.63 | $853,195.98 | | |
| 7/1/2015 | Robin Gene Seim | CFO | Sell | 19,582 | $37.84 | $740,982.88 | | |
| 6/17/2015 | Nhat H Ngo | VP | Sell | 4,067 | $38.78 | $157,718.26 | | |
| 6/2/2015 | James T Judson | Director | Sell | 8,032 | $36.83 | $295,818.56 | | |
| 6/2/2015 | Nhat H Ngo | VP | Sell | 6,375 | $36.80 | $234,600.00 | | |
| 5/26/2015 | Sara J White | Director | Sell | 4,000 | $36.25 | $145,000.00 | | |
| 5/7/2015 | Dan S Johnston | VP | Sell | 7,715 | $34.25 | $264,238.75 | | |
| 2/12/2015 | J Christopher Drew | VP | Sell | 25,000 | $34.62 | $865,500.00 | | |
| 2/6/2015 | Dan S Johnston | VP | Sell | 6,552 | $33.29 | $218,116.08 | | |
| 2/2/2015 | James T Judson | Director | Sell | 5,000 | $31.61 | $158,050.00 | | |
| 1/13/2015 | Gary S Petersmeyer | Director | Sell | 670 | $31.31 | $20,977.70 | | |
| 1/2/2015 | James T Judson | Director | Sell | 5,000 | $32.36 | $161,800.00 | | |
| 1/2/2015 | Robin Gene Seim | CFO | Sell | 1,948 | $32.36 | $63,037.28 | | |
| 12/17/2014 | Marga Ortigas-Wedekind | VP | Sell | 4,080 | $32.20 | $131,376.00 | | |
| 12/15/2014 | Gary S Petersmeyer | Director | Sell | 670 | $33.25 | $22,277.50 | | |
| 12/8/2014 | Nhat H Ngo | VP | Sell | 1,754 | $32.89 | $57,689.06 | | |
| 12/1/2014 | James T Judson | Director | Sell | 5,000 | $31.94 | $159,700.00 | | |
| 11/12/2014 | Randy D Lindholm | Director | Sell | 5,000 | $31.72 | $158,600.00 | | |
| 11/11/2014 | J Christopher Drew | VP | Sell | 37,500 | $31.86 | $1,194,750.00 | | |
| 11/7/2014 | Dan S Johnston | VP | Sell | 27,625 | $31.74 | $876,817.50 | | |
| 11/3/2014 | James T Judson | Director | Sell | 5,000 | $32.27 | $161,350.00 | | |
| 10/3/2014 | Nhat H Ngo | VP | Sell | 2,275 | $28.00 | $63,700.00 | | |
| 10/1/2014 | James T Judson | Director | Sell | 5,000 | $27.02 | $135,100.00 | | |
| 9/15/2014 | Jorge R Taborga | VP | Sell | 944 | $26.37 | $24,893.28 | | |
| 9/15/2014 | Robin Gene Seim | CFO | Sell | 9,347 | $26.32 | $246,013.04 | | |
| 9/2/2014 | James T Judson | Director | Sell | 5,000 | $28.18 | $140,900.00 | | |
| 9/2/2014 | Robin Gene Seim | CFO | Sell | 27,500 | $28.19 | $775,225.00 | | |
| 8/26/2014 | Dan S Johnston | VP | Sell | 6,250 | $28.00 | $175,000.00 | | |
| 8/26/2014 | James T Judson | Director | Sell | 9,913 | $27.91 | $276,671.83 | | |
| 7/9/2014 | Robin Gene Seim | CFO | Sell | 2,442 | $28.21 | $68,888.82 | | |
| 7/1/2014 | James T Judson | Director | Sell | 5,000 | $29.28 | $146,400.00 | | |
| 6/26/2014 | Marga Ortigas-Wedekind | VP | Sell | 2,961 | $28.17 | $83,411.37 | | |
| 6/25/2014 | Nhat H Ngo | VP | Sell | 2,274 | $28.00 | $63,672.00 | | |
| 6/17/2014 | Nhat H Ngo | VP | Sell | 1,420 | $27.70 | $39,334.00 | | |
| 6/10/2014 | Nhat H Ngo | VP | Sell | 1,964 | $26.38 | $51,810.32 | | |
| 6/2/2014 | Gary S Petersmeyer | Director | Sell | 5,000 | $26.45 | $132,250.00 | | |
| 5/21/2014 | Gary Petersmeyer | Director | Sell | 2,000 | $26.51 | $53,020.00 | 17,088 | |
| 5/13/2014 | J Christopher Drew | VP | Sell | 37,500 | $26.08 | $978,000.00 | 151,448 | |
| 5/7/2014 | Dan Johnston | VP | Sell | 4,000 | $25.25 | $101,000.00 | 75,558 | |
| 5/1/2014 | James Judson | Director | Sell | 5,000 | $26.24 | $131,200.00 | 17,945 | |
| 4/8/2014 | Nhat Ngo | VP | Sell | 1,002 | $27.40 | $27,454.80 | 52,896 | |
| 3/18/2014 | Marga Ortigas-Wedekind | VP | Sell | 5,880 | $30.00 | $176,400.00 | 53,445 | |
| 3/18/2014 | Randall Lipps | CEO | Sell | 124,910 | $29.89 | $3,733,559.90 | 220,997 | |
| 12/18/2013 | Nhat Ngo | VP | Sell | 1,462 | $24.43 | $35,716.66 | 45,585 | |
| 12/18/2013 | Randall Lipps | CEO | Sell | 64,739 | $24.30 | $1,573,157.70 | 186,048 | |
| 12/3/2013 | Dan Johnston | VP | Sell | 73,419 | $23.24 | $1,706,257.56 | 74,885 | |
| 11/11/2013 | Randy Lindholm | Director | Sell | 3,587 | $23.00 | $82,501.00 | 26,917 | |
| 11/7/2013 | Dan Johnston | VP | Sell | 8,000 | $22.99 | $183,920.00 | 74,885 | |
| 10/23/2013 | Robin Gene Seim | CFO | Sell | 7,664 | $24.50 | $187,768.00 | | |
| 10/21/2013 | Robin Gene Seim | CFO | Sell | 9,349 | $23.76 | $222,132.24 | | |
| 10/1/2013 | James T Judson | Director | Sell | 5,000 | $23.66 | $118,300.00 | | |
| 9/24/2013 | Randall Lipps | CEO | Sell | 68,204 | $25.00 | $1,705,100.00 | 202,362 | |
| 9/23/2013 | Marga Ortigas-Wedekind | VP | Sell | 4,000 | $25.00 | $100,000.00 | 80,903 | |
| 9/23/2013 | Randall Lipps | CEO | Sell | 5,083 | $25.00 | $127,075.00 | 202,362 | |
| 9/20/2013 | Robin Gene Seim | CFO | Sell | 27,500 | $24.35 | $669,625.00 | 69,700 | |
| 9/18/2013 | Randall Lipps | CEO | Sell | 64,453 | $23.67 | $1,525,602.51 | 202,362 | |
| 9/4/2013 | Nhat H Ngo | VP | Sell | 7,362 | $24.00 | $176,688.00 | | |
| 9/3/2013 | James Judson | Director | Sell | 5,000 | $22.77 | $113,850.00 | 17,945 | |
| 8/20/2013 | James Judson | Director | Sell | 11,724 | $22.74 | $266,603.76 | 17,945 | |
| 8/13/2013 | J Christopher Drew | VP | Sell | 20,000 | $22.83 | $456,600.00 | 131,221 | |
| 8/12/2013 | Donald Wegmiller | Director | Sell | 34,976 | $22.87 | $799,901.12 | 8,002 | |
| 8/7/2013 | Dan Johnston | VP | Sell | 8,000 | $22.92 | $183,360.00 | 74,885 | |
| 8/6/2013 | Randall Lipps | CEO | Sell | 5,321 | $23.00 | $122,383.00 | 211,905 | |
| 8/2/2013 | Randall A Lipps | CEO | Sell | 25,000 | $22.50 | $562,500.00 | | |
| 8/1/2013 | James Judson | Director | Sell | 5,000 | $21.00 | $105,000.00 | 29,669 | |
| 7/19/2013 | Nhat H Ngo | VP | Sell | 41,875 | $21.00 | $879,375.00 | | |
| 7/19/2013 | Randall A Lipps | CEO | Sell | 5,080 | $21.00 | $106,680.00 | | |
| 7/1/2013 | James T Judson | Director | Sell | 5,000 | $20.46 | $102,300.00 | | |
| 7/1/2013 | Robin Gene Seim | CFO | Sell | 13,032 | $20.42 | $266,113.44 | | |
| 6/28/2013 | Marga Ortigas-Wedekind | VP | Sell | 4,545 | $20.00 | $90,900.00 | | |
| 6/28/2013 | Randall A Lipps | CEO | Sell | 25,000 | $20.00 | $500,000.00 | | |
| 6/21/2013 | Nhat H Ngo | VP | Sell | 3,459 | $19.01 | $65,755.59 | | |
| 6/18/2013 | Randall A Lipps | CEO | Sell | 66,378 | $19.10 | $1,267,819.80 | | |
| 6/10/2013 | Randy D Lindholm | Director | Sell | 23,901 | $19.14 | $457,465.14 | | |
| 6/4/2013 | Robin Gene Seim | CFO | Sell | 25,000 | $18.72 | $468,000.00 | | |
| 5/22/2013 | Gary S Petersmeyer | Director | Sell | 2,750 | $18.10 | $49,775.00 | | |
| 5/16/2013 | J Christopher Drew | VP | Sell | 26,000 | $18.69 | $485,940.00 | | |
| 5/14/2013 | J Christopher Drew | VP | Sell | 26,000 | $18.45 | $479,700.00 | | |
| 5/10/2013 | Sara J White | Director | Sell | 7,200 | $18.50 | $133,200.00 | | |
| 5/7/2013 | Dan S Johnston | VP | Sell | 8,000 | $18.44 | $147,520.00 | | |
| 12/3/2012 | Gary S Petersmeyer | Director | Sell | 1,359 | $15.17 | $20,616.03 | | |
(Data available from 1/1/2013 forward)
Omnicell Technologies (NASDAQ OMCL) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Omnicell Technologies (OMCL) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - April 20 at 11:17 AM |
 | Omnicell to Release First Quarter 2018 Earnings Results on April 26, 2018
finance.yahoo.com - April 19 at 4:42 PM |
| Omnicell Technologies (OMCL) Expected to Post Quarterly Sales of $177.37 Million
www.americanbankingnews.com - April 19 at 2:12 AM |
| Omnicell Technologies (OMCL) Expected to Post Earnings of $0.27 Per Share
www.americanbankingnews.com - April 17 at 9:12 PM |
| Omnicell Technologies (OMCL) EVP Dan S. Johnston Sells 11,284 Shares
www.americanbankingnews.com - April 16 at 7:14 PM |
| Analyzing Omnicell Technologies (OMCL) and Teradata (TDC)
www.americanbankingnews.com - April 15 at 9:09 PM |
| Omnicell Technologies (OMCL) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - April 15 at 11:29 AM |
| Omnicell Technologies (OMCL) Insider Sells $33,304.00 in Stock
www.americanbankingnews.com - April 12 at 7:35 PM |
| Omnicell Technologies (OMCL) versus Dell Technologies (DVMT) Financial Contrast
www.americanbankingnews.com - April 12 at 1:29 AM |
| Comparing Omnicell Technologies (OMCL) & NICE Systems (NICE)
www.americanbankingnews.com - April 11 at 8:45 AM |
| Omnicell's Medication Management Automation Portfolio to Be Featured at the American Organization of Nurse Executives 2018 Conference
finance.yahoo.com - April 10 at 9:49 AM |
| Head-To-Head Review: Omnicell Technologies (OMCL) & Capcom (CCOEY)
www.americanbankingnews.com - April 10 at 1:31 AM |
| Omnicell Appoints Scott Seidelmann as Chief Commercial Officer
finance.yahoo.com - April 9 at 9:38 AM |
| Omnicell Technologies (OMCL) Upgraded by BidaskClub to "Hold"
www.americanbankingnews.com - April 7 at 9:29 AM |
| Craig Hallum Reaffirms "Buy" Rating for Omnicell Technologies (OMCL)
www.americanbankingnews.com - April 4 at 1:21 PM |
| Omnicell Technologies (OMCL) Earns Buy Rating from Cantor Fitzgerald
www.americanbankingnews.com - April 3 at 5:16 PM |
| Omnicell Technologies (OMCL) Expected to Announce Quarterly Sales of $177.37 Million
www.americanbankingnews.com - April 2 at 2:08 AM |
| $0.27 Earnings Per Share Expected for Omnicell Technologies (OMCL) This Quarter
www.americanbankingnews.com - March 31 at 9:08 PM |
| Reviewing Omnicell Technologies (OMCL) & Cancer Genetics (CGIX)
www.americanbankingnews.com - March 27 at 3:20 PM |
| Mercyhealth Adopts Omnicell's XR2 Automated Central Pharmacy System to Enhance Patient Safety
finance.yahoo.com - March 27 at 9:49 AM |
| Omnicell (OMCL) Upgraded at BidaskClub
www.americanbankingnews.com - March 24 at 6:46 PM |
| Head to Head Contrast: Omnicell (OMCL) and The Ensign Group (ENSG)
www.americanbankingnews.com - March 23 at 1:32 AM |
| Omnicell To Present At Needham & Company's 17th Annual Healthcare Conference
finance.yahoo.com - March 22 at 4:28 PM |
| Omnicell, Inc. (OMCL) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - March 21 at 11:27 AM |
 | Omnicell to Showcase Industry-Leading Medication Management Automation ...
www.prnewswire.com - March 20 at 4:23 PM |
| Omnicell to Showcase Industry-Leading Medication Management Automation Platform and Solutions at the European Association of Hospital Pharmacists Congress
finance.yahoo.com - March 20 at 9:37 AM |
| Omnicell, Inc. (OMCL) Director Gary S. Petersmeyer Sells 575 Shares
www.americanbankingnews.com - March 16 at 8:52 PM |
| Analysts Expect Omnicell, Inc. (OMCL) Will Announce Quarterly Sales of $177.37 Million
www.americanbankingnews.com - March 16 at 3:27 AM |
| Infirmary Health Adopts Omnicell's Sterile Compounding Solutions and Services
finance.yahoo.com - March 14 at 10:24 AM |
| Omnicell, Inc. (OMCL) Chairman Sells $361,903.06 in Stock
www.americanbankingnews.com - March 8 at 12:31 AM |
| Omnicell (OMCL) Down 12.7% Since Earnings Report: Can It Rebound?
finance.yahoo.com - March 5 at 9:37 AM |
| Martingale Asset Management L P Reduces Stake in Omnicell, Inc. (OMCL)
www.americanbankingnews.com - March 4 at 12:50 PM |
| Arizona State Retirement System Has $3.09 Million Position in Omnicell, Inc. (OMCL)
www.americanbankingnews.com - March 4 at 4:32 AM |
| Omnicell, Inc. (OMCL) Short Interest Down 32.8% in February
www.americanbankingnews.com - March 4 at 2:56 AM |
| Omnicell Opens Center of Excellence in Cranberry Township, Showcasing ...
www.prnewswire.com - March 3 at 5:13 PM |
| Kennedy Capital Management Inc. Has $22.58 Million Position in Omnicell, Inc. (OMCL)
www.americanbankingnews.com - March 2 at 5:27 PM |
| Omnicell, Inc. (OMCL) Holdings Reduced by Snyder Capital Management L P
www.americanbankingnews.com - March 2 at 1:50 PM |
 | B. Braun To Showcase Latest Information Technology Capabilities at HIMSS18
feeds.benzinga.com - March 1 at 2:43 PM |
| King Luther Capital Management Corp Has $3.46 Million Position in Omnicell, Inc. (OMCL)
www.americanbankingnews.com - March 1 at 11:42 AM |
| Omnicell Opens Center of Excellence in Cranberry Township, Showcasing Innovation and Industry-Leading Medication Management Platform
finance.yahoo.com - March 1 at 9:07 AM |
| Omnicell Inc (OMCL) Files 10-K for the Fiscal Year Ended on December 31, 2017
finance.yahoo.com - February 27 at 5:05 PM |
| Head-To-Head Analysis: NantHealth (NH) & Omnicell (OMCL)
www.americanbankingnews.com - February 27 at 10:10 AM |
| Omnicell's Industry-Leading Medication Management Automation Platform and Solutions to Be Featured at HIMSS18
finance.yahoo.com - February 27 at 9:25 AM |
| Omnicell, Inc. (OMCL) Expected to Post Quarterly Sales of $177.37 Million
www.americanbankingnews.com - February 27 at 7:06 AM |
| Omnicell, Inc. (OMCL) Shares Sold by Champlain Investment Partners LLC
www.americanbankingnews.com - February 27 at 5:38 AM |
| 796,115 Shares in Omnicell, Inc. (OMCL) Acquired by Carillon Tower Advisers Inc.
www.americanbankingnews.com - February 27 at 5:32 AM |
| Omnicell, Inc. (OMCL) Stake Lifted by Monroe Bank & Trust MI
www.americanbankingnews.com - February 26 at 3:50 PM |
| $0.26 EPS Expected for Omnicell, Inc. (OMCL) This Quarter
www.americanbankingnews.com - February 25 at 7:08 PM |
| Omnicell, Inc. (OMCL) Given Consensus Rating of "Hold" by Analysts
www.americanbankingnews.com - February 24 at 2:50 PM |
 | Commit To Purchase Omnicell At $35, Earn 6.6% Annualized Using Options
www.nasdaq.com - February 23 at 4:58 PM |
Omnicell Technologies (NASDAQ:OMCL) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Omnicell Technologies (NASDAQ:OMCL) Income Statement, Balance Sheet and Cash Flow Statement
Omnicell Technologies (NASDAQ OMCL) Stock Chart for Friday, April, 20, 2018
Loading chart…
